IN8bio Q3 net loss widens as R&D expenses rise
INAB•IN8bio reported a third-quarter net loss of $4.59 million, or $0.24 per basic share, and operating expenses of $4.72 million. The company appointed Oxana Polyakova as SVP of Research & Development.
1. Quarterly results
IN8bio's third-quarter net loss widened year over year as research and development expenses increased. The company reported a net loss of $4.59 million, a loss of $0.24 per basic share and operating expenses of $4.72 million.
2. Pipeline and leadership
The company continued preclinical development of INB-619 for oncology and autoimmune indications. It appointed Oxana Polyakova as SVP of Research & Development to accelerate its γδ TCE pipeline.
